![David A. Zarling](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David A. Zarling
Chief Executive Officer at Colby Pharmaceutical Co.
Profile
David A.
Zarling is the founder of Colby Pharmaceutical Co. Prior to that, he worked as the President & Chief Executive Officer of Pangene Corp.
and as a Program Director at SRI International.
He also served as an Adjunct Associate Professor at The University of California, San Francisco.
Zarling received his undergraduate and graduate degrees from Dartmouth College and an MBA from Pepperdine University.
He also holds a doctorate from Baylor College of Medicine.
David A. Zarling active positions
Companies | Position | Start |
---|---|---|
Colby Pharmaceutical Co.
![]() Colby Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs. | Chief Executive Officer | 31/12/2003 |
Former positions of David A. Zarling
Companies | Position | End |
---|---|---|
SRI International
![]() SRI International Miscellaneous Commercial ServicesCommercial Services SRI International provides contract research and development services. It is an independent, nonprofit research institute conducting client-sponsored research and development for government agencies, commercial businesses, foundations, and other organizations. The company was founded in 1946 and is headquartered in Menlo Park, CA. | Corporate Officer/Principal | - |
The University of California, San Francisco | Corporate Officer/Principal | - |
Pangene Corp.
![]() Pangene Corp. Pharmaceuticals: MajorHealth Technology Pangene Corp. develops oncology drugs based on its DNA repair and recombination platform. The company is headquartered in Mountain View, CA. | President | - |
Training of David A. Zarling
Dartmouth College | Graduate Degree |
Pepperdine University | Masters Business Admin |
Baylor College of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
SRI International
![]() SRI International Miscellaneous Commercial ServicesCommercial Services SRI International provides contract research and development services. It is an independent, nonprofit research institute conducting client-sponsored research and development for government agencies, commercial businesses, foundations, and other organizations. The company was founded in 1946 and is headquartered in Menlo Park, CA. | Commercial Services |
Pangene Corp.
![]() Pangene Corp. Pharmaceuticals: MajorHealth Technology Pangene Corp. develops oncology drugs based on its DNA repair and recombination platform. The company is headquartered in Mountain View, CA. | Health Technology |
Colby Pharmaceutical Co.
![]() Colby Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs. | Health Technology |
- Stock Market
- Insiders
- David A. Zarling